Skip to main content

Table 1 Characteristics of the 7 included studies

From: Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis

References Study design Sample size Intervention Follow-up time (months) Outcomes
SCRT/CCT LCCRT
Markovina et al. [20] Prospective study 138 25 Gy in 5 fractions, 4 cycles FOLFOX, TME median 45 Gy in 25 fractions with concurrent CT, TME 49.4/54.3 OS, DFS, LRR, DMR, pCR rate, ypTNM, downstaging, sphincter preserve rate, R0 resection rate, toxicity
Chung et al. [21] Retrospective study 72 25 Gy in 5 fractions with concurrent CT, 3 cycles CT, TME 50.4 Gy in 28 fractions with concurrent CT, TME 25 OS, DFS, LRR, DMR, pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity
Ciseł et al. [17] Randomized controlled trials 515 25 Gy in 5 fractions, 3 cycles FOLFOX4, TME 50.4 Gy in 28 fractions with concurrent CT, TME 84.0 OS, DFS, LRR, DMR, pCR rate, ypTNM, sphincter preserve rate, R0 resection rate, toxicity
Bahadoer et al. [9] Randomized controlled trials 912 25 Gy in 5 fractions, 6 cycles CAPOX or 9 cycles FOLFOX, TME 50–50.4 Gy in 25–28 fractions with concomitant CT, TME 55.2 OS, DFS, LRR, DMR, pCR rate, ypTNM, sphincter preserve rate, R0 resection rate, toxicity
Thakur et al. [22] Prospective study 28 25 Gy in 5 fractions, 2 cycles CT, TME 45 Gy in 25 fractions with concurrent CT, TME 22.6 OS, DFS, LRR, DMR, pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity
Aghili et al. [19] Prospective study 60 25 Gy in 5 fractions with concurrent XELOX, 3–4 weeks XELOX, TME 50–50.4 Gy in 25–28 fractions with concomitant CT, 3–4 weeks XELOX, TME 18 pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity
Chakrabarti et al. [18] Randomized controlled trials 140 25 Gy in 5 fractions, 2 cycles XELOX, TME 50–50.4 Gy in 25–28 fractions with concomitant CT, TME N/A pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity
  1. SCRT/CCT, short-course radiotherapy followed by consolidation chemotherapy; LCCRT, long-course chemoradiotherapy; CT, chemotherapy; TME, total mesorectal excision; OS, overall survival; DFS, disease-free survival; LR: local recurrence; DM, distal metastasis rate; pCR, pathologic complete response; ypTNM, adjuvant pathologic staging; N/A, not available